Treatment with combined NMDA and non-NMDA antagonists to reduce

Details Treatment with combined NMDA and non-NMDA antagonists to reduce Treatment with combined NMDA and non-NMDA antagonists to reduce

1992-05-01

1998-11-10

Weddington, Kevin E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

514270, 514289, 514315, 514318, A61K 3154, A61K 31515, A61K 3144, A61K 31445

Patent

active

058344659

ABSTRACT:
This invention involves a pharmaceutical mixture for preventing or reducing excitotoxic brain damage caused by hypoxia/ischemia (such as stroke) and various other factors. This mixture comprises an NMDA antagonist and a non-NMDA antagonist, both of which penetrate blood-brain barriers (BBB's) and which, in combination, provide greater protection against excitotoxic damage than can be provided by any quantity of either agent by itself. Suitable NMDA antagonists can be either competitive antagonists which bind directy to the NMDA binding site in the NMDA receptor complex, or non-competitive agents that interact with other binding sites such as the PCP, glycine, or polyamine binding sites. Suitable non-NMDA antagonists include a quinoxalinedione compound referred to as NBQX, and a 2,3-benzodiazepine compound referred to as GYKI 52466. If an NMDA antagonist is used which is stronger than dextromethorphan, the mixture of an NMDA and a non-NMDA antagonist preferably should be administered in combination with a third agent that functions as a "safening agent" to prevent or reduce the neurotoxic side effects caused by strong NMDA antagonists. Two classes of safening agents have been identified: (1) anti-cholinergic agents such as scopolamine and, (2) barbiturates which act as direct agonists of gamma-amino-butyric acid (GABA) receptors, such as secobarbital, pentobarbital, and thiamylal.

REFERENCES:
patent: 4806543 (1989-02-01), Choi
patent: 4833148 (1989-05-01), Olney
patent: 4888347 (1989-12-01), Woodruff et al.
Boast, C.A., Neurology and Neurobiology 46: 691-698 (1988).
Honore, T., et al, Science 241: 701-703 (1988).
Drejer, J. and Honore, T., Neurosci. Letters 87: 104-108 (1988).
Price, M.T., et al, Society of Neuroscience Abstracts 14: 418 (abstract #168.9; Nov. 1988).
Olney, J.W., et al, J. Neurosci. 9: 1701 (1989).
Honore, T., et al, J. Neurochem. 52 (Suppl.): abstract S42-A (1989).
Sheardown, M.J., et al, Science 247: 571-574 (1990).
I. Tarnawa et al, pp. 538-546 in Labee and Rosenthal, eds., Amino Acids: Chemistry, Biology and Medicine (1990).
Zeevalk, G.D. and Nicklas, W.J., J Pharmacol Exp Ther 253(3): 1285-1292 (1990).
Rothman, S.M., et al, in Glutamate, Cell Death and Memory (P Ascher et al, eds., Springer-Verlag, Berlin Heidelberg, 1991).
Goldberg, M.P., et al, J Pharmacol Exp Ther 243(2): 784-791 (1987).
Goldberg, M.P., et al, J Pharmacol Exp Ther 245 (2): 1081-1086 (1988).
Choi, D.W., et al, J Pharmacol Exp Ther 242(2): 713-720 (1987).
Monyer, H., et al, Brain Res 483: 347-354 (1989).
Buchan, A. and Pulsinelli, W.A., J. Neuroscience 10: 311-316 (1990).
Buchan, A.M., et al, Neurosci. Letters 132: 255-258 (1991).
Sheardown, M.J., et al, pp. 245-253 in Krieglstein, J., and Oberpichler, H., eds., Pharmacology of Cerebral Ischemia 1990 (Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany, 1990).
Michenfelder, J., et al, Brain Research 481: 228-234 (1989).
Lanier, W., et al, Anesthes. Rev. 15: 36-37 (1988).
Nellgard, B. and Wieloch, T., J Cereb Blood Flow Metab 12: 2-11 (1992).
Nellgard, B., et al, Anesthesiology 75: 279-287 (1991).
Olney, J.W., et al, Science 244: 1360-1362 (1989).
Mosinger, J.L. & Olney, J.W., Society of Neuroscience Abstracts 15: 45 (abstract #23.22; Oct. 1989).
Mosinger, J.L. and Olney, J.W., Exper. Neurol. 105: 110-113 (1989).
Salt, T.E. and Eaton, S.A., Exper. Brain Research 77 (3): 646-652 (1989).
Boast, Neurology and Neurobiology 46: 691-698 (1988).
Honore et al., Science 241: 701-703 (1988).
Drejer et al., Neurosci. Letters 87: 104-108 (1988).
Price et al., Society of Neuroscience Abstracts 14: 418 (ab #168.9) 1988.
Olney et al. Eur. J. Pharmacol. 142: 319-320 (1987).

Affiliated with

Also associated with

Rating

Treatment with combined NMDA and non-NMDA antagonists to reduce does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment with combined NMDA and non-NMDA antagonists to reduce , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment with combined NMDA and non-NMDA antagonists to reduce will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1516958